drugset
drugset / Trial / NCT00813332

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

NCT00813332 ↗

Phase 4 Unknown 300 enrolled Simcere Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of Endostar (Recombinant Human Endostatin) combined with Docetaxel and single Docetaxel through multi-center, double-blinding, randomized controlled, phase Ⅳ clinical trial for NSCLC cases who have obvious progressive disease or intolerant adverse effects in first-line chemotherapy.

Timeline

Start
2008-10
Primary completion
2009-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 7.5 mg/m2 Intravenous
Background Docetaxel Small molecule 75 mg/m2 Intravenous

Indications

non-small cell lung carcinoma